57. Larochell P. Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension. *Am J Hypertens* 1996; 9: 551-9
58. Dominguez LJ, Barbagallo M, Kattah W, et al. Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. *Am J Hypertens* 1995; 8: 808-14
59. Schmieder RE, Ruddel H, Schlebusch H, et al. Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy. *Am J Hypertens* 1992 May; 5: 318-21
60. Bignotti M, Lamponi M. Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension [in Italian]. *Minerva Cardioangiol* 1996; 44: 331-5
61. Erley CM, Haefele U, Heyne N, et al. Microalbuminuria in essential hypertension: reduction by different antihypertensive drugs. *Hypertension* 1993; 21: 810-5
62. Ruilope LM, Alcazar JM, Hernandez E, et al. Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. *Kidney Int* 1994; 45 Suppl. 45: S171-3

Correspondence and reprints: Dr *Josep Redon*, Hypertension Clinic, Internal Medicine, Hospital Clinico Universitario, Avenida Blasco Ibañez, 17, 46010 Valencia, Spain.
E-mail: josep.redon@uv.es

Erratum

Vol. 54, No. 3, page 428: The second sentence in the third paragraph of section 6.3.6 should read 'The switch from oral administration to intermittent intravenous pulses of cyclophosphamide (500 to 1000 mg/m² of body surface area) . . .'.
[Schroeder JO, Euler HH. Recognition and Management of Systemic Lupus Erythematosus. *Drugs* 1997 Sep; 54 (3): 422-34]